Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    28
    ...
ATC Name B/G Ingredients Dosage Form Price
J01CR02 MEGAMOX-JPI G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 456,906 L.L
J01MA02 CIPROCIN G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 240,548 L.L
J07AH MENFIVE G Meningococcal (serogroups A, C, Y, W, X) Polysaccharide conjugate vaccine - Injectable freeze dried powder + diluent 3,527,587 L.L
L02BG06 EXEMESTANE G Exemestane - 25mg 25mg Tablet, film coated 1,222,897 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,057,604 L.L
N03AX12 VOLAR G Gabapentin - 300mg 300mg Capsule 1,100,607 L.L
R01AA07 DECOZAL G Xylometazoline HCl - 0.05% 0.05% Metered dose spray 155,886 L.L
R06AE07 FINALLERG G Cetirizine (dihydrochloride) - 10mg 10mg Tablet, film coated 342,680 L.L
V07AB01 STERILE WATER FOR INJECTION USP G Water for injection - Water for injection, irrigation 264,311 L.L
A02BC02 GASTROPAN G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,104,639 L.L
B05CX01 SERUFLEX DEXTROSE 5% INJECTION, USP G Glucose - 5% 5% Injectable solution 193,062 L.L
C03DA05 KERENDIA G Finerenone - 10mg 10mg Tablet, film coated 6,353,687 L.L
C09CA04 CONVERIUM G Irbesartan - 150mg 150mg Tablet 585,915 L.L
C10AA05 TARDEN G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,055,876 L.L
D08AC52 CYTEAL Solution Antiseptique G Chlorhexidine digluconate - 0.5ml/100ml, Hexamidine - 0.1g/100ml, Chlorocresol - 0.3g/100ml Solution 641,409 L.L
G04BE08 TADALAGEN G Tadalafil - 20mg 20mg Tablet, film coated 1,032,839 L.L
J01CR02 MOXICLAV G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet 430,030 L.L
J01MA02 CIPRODAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 392,402 L.L
L02BG06 EXEMESTANE ARROW G Exemestane - 25mg 25mg Tablet, film coated 3,386,483 L.L
N01BB54 PRILA G Prilocaine - 2.5% w/w, Lidocaine - 2.5% w/w Cream 1,163,768 L.L
N03AX12 GABAMOX G Gabapentin - 400mg 400mg Capsule, hard 1,233,647 L.L
R01AA07 DECOZAL G Xylometazoline HCl - 0.05% 0.05% Metered dose spray 108,851 L.L
V07AB01 STERILE WATER FOR IRRIGATION G Water for Irrigation - Water for injection, irrigation 203,481 L.L
A02BC02 GASTROPAN G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 581,884 L.L
B05CX01 SOLUFLEX DEXTROSE 5% INJECTION USP G Glucose - 5% 5% Injectable solution 186,167 L.L
C03DA05 KERENDIA G Finerenone - 20mg 20mg Tablet, film coated 6,353,687 L.L
C09CA04 GIZLAN G Irbesartan - 150mg 150mg Tablet, film coated 748,520 L.L
C10AA05 TORVACOL 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, coated 2,363,819 L.L
D08AX01 EAU OXYGENEE 10/120 G Hydrogen peroxide - 10V 10V Solution 119,026 L.L
G04BE08 TADAPRESS G Tadalafil - 20mg 20mg Tablet, film coated 13,621,308 L.L
    ...
    28
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025